# Debate Matchup Judgment Report

**Gemini 3.1 Pro Preview** vs **Grok 4.3**

- Paired result: **Gemini 3.1 Pro Preview**
- Mean entertainment: `7.00 / 10`
- Judge decisions: `8` across two side-swapped debates

**Motion:** Public healthcare systems deliver better population health outcomes per dollar than predominantly private insurance systems.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0110__gemini-3.1-pro-preview__grok-4.3__s0__tpl_placement_active_20260320f.md): PRO = **Gemini 3.1 Pro Preview**, CON = **Grok 4.3**
- [Debate B transcript](../../../transcripts/prop_0110__grok-4.3__gemini-3.1-pro-preview__s1__tpl_placement_active_20260320f.md): PRO = **Grok 4.3**, CON = **Gemini 3.1 Pro Preview**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0110__gemini-3.1-pro-preview__grok-4.3__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Gemini 3.1 Pro Preview**, CON = **Grok 4.3**
- Judged result: Unanimous `4-0` for **Gemini 3.1 Pro Preview**.
- Entertainment scores: `7`, `6`, `7`, `7`
- Mean signed raw margin (PRO+): `+1.75`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 4.6 (high) | A = Grok 4.3 (CON); B = Gemini 3.1 Pro Preview (PRO) | Gemini 3.1 Pro Preview | +1.5 | +1.50 | 7.0 |
| GPT-5.5 (high) | A = Gemini 3.1 Pro Preview (PRO); B = Grok 4.3 (CON) | Gemini 3.1 Pro Preview | +1.8 | +1.93 | 6.0 |
| Kimi K2.6 | A = Gemini 3.1 Pro Preview (PRO); B = Grok 4.3 (CON) | Gemini 3.1 Pro Preview | +2.2 | +2.20 | 7.0 |
| Qwen 3.6 Max Preview | A = Gemini 3.1 Pro Preview (PRO); B = Grok 4.3 (CON) | Gemini 3.1 Pro Preview | +1.5 | +1.50 | 7.0 |

### Judge Notes

- **Claude Sonnet 4.6 (high)** (A = Grok 4.3 (CON); B = Gemini 3.1 Pro Preview (PRO)): PRO (Side B) built and maintained the cleaner path to victory across all five rounds. Three moments were decisive. First, B's "invisible queue" reframe in Rebuttal 1 effectively neutralized CON's central access-speed argument: price rationing excludes people just as surely as a waiting list does, and the excluded patients generate catastrophically expensive emergencies later, worsening both aggregate health and per-dollar efficiency. CON never squarely answered this. Second, B's Q2 forced CON into an awkward position: CON's own response to drug pricing—that public systems acquire identical therapies at lower prices but that this undercuts future innovation—effectively conceded that public systems achieve a better return on today's spending. CON tried to escape through a future-value reframe, arguing tomorrow's pipeline shrinks, but this is a different metric than the motion's current per-dollar population health test. B correctly exploited this in B4.2–4.3 and the closing. Third, B's Q1 directly undermined CON's prevention-investment claim by pointing out that employer-based coverage creates constant plan churn, destroying the insurer's incentive to invest in decades-long chronic disease management. CON's A1 response pivoted to short-payback prevention (diabetes management cutting claims within months), which was a partial concession rather than a direct refutation. CON's strongest remaining argument—that private reimbursement signals drive innovation, widening the long-run toolkit—has genuine intellectual weight but is temporally misaligned with the motion's current-period metric and was never reanchored to present per-dollar outcomes. CON also left the population framing largely unchallenged: fast, high-quality care for insured patients does not establish superior population health when millions are structurally priced out. PRO consistently returned to that word and CON never neutralized it. CON was competent and occasionally sharp, but left too many live burdens unanswered.
  Most decisive rebuttal noted: The most decisive exchange was B's Q2 (B3.2) combined with B4.2–4.3: B asked whether paying significantly less for the same life-saving treatments mathematically proves superior ROI per the motion's metric. CON's answer conceded the factual premise but argued future innovation requires high prices. B then crystallized this as CON admitting public systems get the same therapies at lower cost while CON's defense amounts to a different claim about a different time horizon—not the current per-dollar population health metric the motion actually asks about. This moment shifted the burden of the innovation argument from a genuine counterweight into an implicit concession on the live metric.
- **GPT-5.5 (high)** (A = Gemini 3.1 Pro Preview (PRO); B = Grok 4.3 (CON)): Side A won by keeping the debate focused on the motion's key metric: population health outcomes per dollar. A gave clearer mechanisms for why public systems reduce waste, lower prices, and improve access through early intervention. B had a plausible innovation and waiting-list route, but it stayed mostly asserted and did not overcome A's price-rationing response or the access problem for the whole population. B's defense of price-based access was especially weak because it conflated ability to pay with medical urgency.
  Most decisive rebuttal noted: A's response that private systems ration by price, creating an invisible queue that delays care for poorer patients, was the most decisive exchange. It directly answered B's waiting-list argument while tying the comparison back to population-wide outcomes and cost efficiency.
- **Kimi K2.6** (A = Gemini 3.1 Pro Preview (PRO); B = Grok 4.3 (CON)): Side A won by consistently tying the debate back to the stated metric—population health outcomes per dollar—and exposing Side B’s failure to defend on those terms. Side A’s rebuttal reframing private cost-sharing as an “invisible queue” that produces catastrophic, expensive emergencies remained live because Side B never showed how price rationing improves aggregate population health. Side A’s pressure question on drug prices forced Side B to concede that public systems acquire the same therapies for less, and Side B could only reply with an off-metric innovation-subsidy argument that implicitly admitted worse current ROI. Side B also failed to answer the employment-turnover challenge to long-term private prevention incentives, leaving a central causal mechanism undefended.
  Most decisive rebuttal noted: Side A’s invisible queue rebuttal (Turn 3, A2.2) and the subsequent pressure-to-concede on identical therapies at lower public prices (Turn 5 Q2 / Turn 7 A4.2–A4.3), which Side B never rebutted within the motion’s metric.
- **Qwen 3.6 Max Preview** (A = Gemini 3.1 Pro Preview (PRO); B = Grok 4.3 (CON)): Side A wins by tightly anchoring the debate to the motion's specific metric: population health outcomes per dollar. A successfully isolates the delivery efficiency question from CON's broader R&D subsidy frame, demonstrating that paying less for the same therapies mathematically improves the per-dollar return. A's reframing of private deductibles as an invisible queue that harms aggregate population health directly neutralizes CON's speed and queue advantage. While CON competently defends innovation and capacity expansion, it never fully answers how pricing out millions or funding corporate overhead aligns with the population and per-dollar burdens. A's pressure responses and closing crystallization were sharper, more adaptive, and decisively resolved the central clash.
  Most decisive rebuttal noted: Side A's Rebuttal 1 and Rebuttal 2 exchange on rationing and drug pricing. A's contrast between visible queues (public) and invisible queues (private price rationing) effectively flipped CON's access argument, while A's strict isolation of the delivery-per-dollar metric neutralized CON's innovation defense by forcing a concession that public systems acquire the same treatments at lower costs, cleanly winning the efficiency weighing.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0110__grok-4.3__gemini-3.1-pro-preview__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **Grok 4.3**, CON = **Gemini 3.1 Pro Preview**
- Judged result: Split `2-2`.
- Entertainment scores: `7`, `7`, `7`, `8`
- Mean signed raw margin (PRO+): `-0.03`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 4.6 (high) | A = Gemini 3.1 Pro Preview (CON); B = Grok 4.3 (PRO) | Gemini 3.1 Pro Preview | -1.2 | -1.20 | 7.0 |
| GPT-5.5 (high) | A = Grok 4.3 (PRO); B = Gemini 3.1 Pro Preview (CON) | Grok 4.3 | +1.2 | +1.29 | 7.0 |
| Kimi K2.6 | A = Grok 4.3 (PRO); B = Gemini 3.1 Pro Preview (CON) | Gemini 3.1 Pro Preview | -1.1 | -1.10 | 7.0 |
| Qwen 3.6 Max Preview | A = Grok 4.3 (PRO); B = Gemini 3.1 Pro Preview (CON) | Grok 4.3 | +1.0 | +1.00 | 8.0 |

### Judge Notes

- **Claude Sonnet 4.6 (high)** (A = Gemini 3.1 Pro Preview (CON); B = Grok 4.3 (PRO)): Side A (CON) built the stronger cumulative case across the exchange. Its most decisive weapon was the free-riding argument: when Side B explicitly conceded in [B2.3] that public systems acquire innovations without paying the margins that fund their creation, Side A immediately weaponized that admission in [A2.1] and [A4.1], arguing the apparent per-dollar efficiency of public systems is a mathematical illusion underwritten by private R&D ledgers. Side B's answer in [B4.1] — redirecting administrative savings and relying on government grants — was notably vague and failed to address Side A's specific challenge about high-risk clinical trial costs [A4.5], leaving the free-riding route genuinely live at the close. Side B also conceded "acute survival gaps, where present" in [B4.2], a significant admission on the motion's own metric, which Side A exploited effectively in both Rebuttal 2 and its closing. Side B's second rebuttal was also significantly shorter than the cap (216 of 340 words), leaving burdens inadequately addressed. Side A's rebuttals were consistently sharper, exploiting opponent language precisely and framing the stakes memorably ("managed decline," "rationing masquerading as universal access"). Side B did establish a plausible empirical foundation — administrative overhead, cream-skimming, Canada vs. US comparisons — and its pressure questions were well-formed, but it never neutralized the free-riding critique or recovered from the acute care concession. The debate is competitive but CON's cleaner exploitation of live admissions and stronger rebuttal execution across multiple rounds tips the balance clearly in its favor.
  Most decisive rebuttal noted: Side A's exploitation of [B2.3] in [A2.1]: when Side B openly stated public systems acquire medical advances without paying the innovation margins, Side A immediately turned this into a structural concession that public efficiency is illusory — a turn that Side B's vague answer about government grants and "stable volume-based markets" never adequately neutralized, keeping the free-riding route live through the closing.
- **GPT-5.5 (high)** (A = Grok 4.3 (PRO); B = Gemini 3.1 Pro Preview (CON)): Side A wins because it stayed closer to the motion’s population-health-per-dollar metric: administrative savings, universal risk pooling, lower financial barriers, and prevention remained live and comparatively underanswered. Side B’s free-riding and rationing arguments were rhetorically sharp, but they leaned on broad assertions about innovation, acute survival, and waitlists without proving that predominantly private insurance systems produce better overall population outcomes per dollar once their much higher costs are counted.
  Most decisive rebuttal noted: Side A’s comparison between private cost-based rationing and public queues was the key exchange: it neutralized Side B’s claim that public systems uniquely deny care and refocused the debate on aggregate prevention and access rather than isolated acute interventions.
- **Kimi K2.6** (A = Grok 4.3 (PRO); B = Gemini 3.1 Pro Preview (CON)): Side B won by exposing a structural flaw in A's per-dollar comparison: public systems appear efficient partly because they suppress prices for innovations developed under private margins and ration timely acute care. A conceded both points—admitting public systems acquire advances without paying innovation margins [A2.3] and acknowledging acute survival gaps [A4.2]—and never offered a credible alternative account of how high-risk clinical development would be funded without private returns. While A's Canada-vs.-US population metrics were intuitively compelling, B successfully framed those outcomes as relying on a hidden subsidy and wait-list rationing that A could not square with the motion's standard. B's rebuttals were sharper, more consistent, and better crystallized in the closing.
  Most decisive rebuttal noted: B2.1/B4.1 turning A's admission that public systems "acquire medical advances without paying the margins that fund their creation" into the sustained free-riding thesis, culminating in B4.5's point that government grants do not cover the massive clinical-trial costs that private margins fund.
- **Qwen 3.6 Max Preview** (A = Grok 4.3 (PRO); B = Gemini 3.1 Pro Preview (CON)): Side A wins by maintaining tighter discipline on the resolution's explicit metric: population health outcomes per dollar. While Side B landed sharp rhetorical blows on wait times and the free-rider problem in medical innovation, Side A successfully weighed the debate toward aggregate preventive care, risk pooling, and downstream cost avoidance. Side B's push to evaluate acute care survival, though compelling, partially shifted the goalposts away from population-level indicators and never fully proved that private systems deliver better health per dollar once high R&D margins, administrative duplication, and cost-rationing are factored into the denominator. Side A's Rebuttal 2 directly answered the pressure questions in the required A1/A2 format and crystallized why prevention and broad deployment yield superior returns on the motion's terms. Side B's rhetoric was more memorable, but Side A's metric alignment and comparative weighing provided the cleaner, more resolutionally grounded path to victory.
  Most decisive rebuttal noted: The exchange over rationing mechanisms and innovation funding. Side B's pressure that public systems free-ride on private R&D margins was the debate's strongest challenge, but Side A's response in Rebuttal 2 successfully contained it by redirecting the clash to aggregate population metrics and downstream cost spirals from delayed care. By showing how high private margins shrink net health returns per dollar, Side A neutralized the innovation attack and kept the evaluation anchored to the motion's population-health standard.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0110`
- Side-swap group ID: `prop_0110__gemini-3.1-pro-preview__grok-4.3__tpl_placement_active_20260320f`
- Raw paired winner: **Gemini 3.1 Pro Preview**
- Mean normalized margin for Gemini 3.1 Pro Preview: `+0.89`
- Complete side swap: `yes`
- Included in ratings: `yes`
